FDA grants ODD to Nexcella’s multiple myeloma treatment
The drug is currently being assessed in a phase 1b/2a clinical trial
Read More
Tag: multiple myeloma
Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’
Updated study results showed an overall response rate of 98% with a longer-term follow-up at a median of 18 months
Read More
Janssen seeks EU approval for first CAR-T therapy cilta-cel
Cilta-cel is an investigational CAR-T cell therapy for the treatment of relapsed/refractory multiple myeloma
Read More
EC approves new Sarclisa indication
Sarclisa has been approved in combination with a standard of care regimen for relapsed multiple myeloma
Read More
FDA green light for Sarclisa combo in multiple myeloma
CD38 inhibitor approved in combination with carfilzomib and dexamethasone
Read More
FDA green light for BMS, bluebird bio’s CAR-T therapy Abecma in multiple myeloma
CAR-T therapy cleared for use in adults with relapsed or refractory multiple myeloma
Read More
NICE recommends Kyprolis triple combination treatment for multiple myeloma
Kyprolis plus lenalidomide and dexamethasone approved as a second-line treatment
Read More
NICE recommends Revlimid for newly diagnosed multiple myeloma patients
Cost-effectiveness agency initially turned down the drug in this setting
Read More
NICE backs use of new treatment for multiple myeloma
Sanofi’s Sarclisa gets the final green light for use by the NHS with funding from the CDF
Read More
Sanofi’s Sarclisa bags NICE recommendation
Treatment is approved for relapsed/refractory multiple myeloma
Read More
NICE turns down Celgene’s Revlimid as multiple myeloma maintenance treatment
The drug’s cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded
Read More
GSK bags EU approval for Blenrep
Blenrep is a first-line inhibitor of BCMA, a cell-surface protein that plays a crucial role in the survival of plasma cells and is expressed on multiple myeloma cells
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
